Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1612 1613 1629
This examiner grants 25% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18006894 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Final Rejection | Novartis AG |
| 18018148 | SUBSTITUTED PYRROLO-PYRIDINONE DERIVATIVES AND THERAPEUTIC USES THEREOF | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18269854 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Non-Final OA | UNM RAINFOREST INNOVATIONS |
| 18032648 | METHOD FOR TREATING ALS/FTD THROUGH DEGRADATION OF RNA REPEAT EXPANSION | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18247014 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Non-Final OA | AstraZeneca AB |
| 18179838 | SOLID FORMS, SALTS, AND PROCESSES OF PREPARATION OF A CDK2 INHIBITOR | Non-Final OA | Incyte Corporation |
| 18245594 | PYRIDO[2,3-D]PYRIMIDIN-4-AMINES AS SOS1 INHIBITORS | Non-Final OA | Bayer Aktiengesellschaft |
| 18246100 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | Non-Final OA | Auckland UniServices Limited |
| 18031688 | COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | Non-Final OA | Blueprint Medicines Corporation |
| 18560991 | DOSAGE REGIMENS FOR ECUBECTEDIN | Non-Final OA | PHARMA MAR S.A. |
| 18017666 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Final Rejection | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
| 18229662 | QUINAZOLINE PAN-KRas INHIBITORS | Non-Final OA | Mirati Therapeutics, Inc. |
| 18005237 | PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD | Final Rejection | JIANGSU KANION PHARMACEUTICAL CO., LTD. |
| 17907722 | THERAPEUTIC AGENT FOR CORONAVIRUS INFECTION | Non-Final OA | FUJIFILM Toyama Chemical Co., Ltd. |
| 18552289 | PHARMACEUTICAL COMPOSITION FOR SUPPRESSING TMPRSS2 EXPRESSION | Non-Final OA | SBI Pharmaceuticals Co., Ltd. |
| 18005961 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | Non-Final OA | GW Research Limited |
| 18005960 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | Non-Final OA | GW Research Limited |
| 18264424 | PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Non-Final OA | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company |
| 18351439 | COMBINATION THERAPIES OF WDR-5 INHIBITORS AND PD-1 INHIBITORS | Non-Final OA | HUYABIO International, LLC |
| 18260670 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | Non-Final OA | Caraway Therapeutics, Inc. |
| 18259509 | EFINACONAZOLE ORAL COMPOSITION | Non-Final OA | DAEBONG LS CO., LTD. |
| 18123009 | PYRIDOPYRIDINES AND DERIVATIVES THEREOF AS SELECTIVE KINASE INHIBITORS | Non-Final OA | University of Sharjah |
| 18253252 | SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Non-Final OA | Fochon Biosciences, Ltd. |
| 18140863 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | Non-Final OA | Aprinoia Therapeutics Limited |
| 18032758 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | Non-Final OA | VAN ANDEL RESEARCH INSTITUTE |
| 18031077 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | Final Rejection | NEOMORPH, INC. |
| 18248278 | PHARMACEUTICALS FOR COVID19 TREATMENT | Final Rejection | NANTCELL, INC. |
| 18248129 | PROSTAGLANDIN RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF A CORONAVIRUS INFECTION SUCH AS COVID-19 | Non-Final OA | MEDETIA |
| 18028157 | CRYSTALLINE POLYMORPH FORM A OF A JAK INHIBITORAND METHODS FOR ITS PREPARATION | Non-Final OA | ACLARIS THERAPEUTICS, INC. |
| 17995418 | METHODS OF TREATMENT USING ANTIFOLATES AND PHARMACEUTICAL FORMULATIONS COMPRISING ANTIFOLATES | Non-Final OA | EMPHASCIENCE, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy